Skip to content
Screener

Janux Therapeutics JANX Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$10.0M
EPS-$0.39Beat by $0.21
EPS estimate-$0.60

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$8.0M
EPS estimate-$0.45

Financials

Q3 2025

Income statement

See full
Revenue$10.0M+2,178%
Operating income-$35.3M+1.6%
Net income-$24.3M+13.4%
EPS (diluted)-$0.39+23.5%

Balance sheet

See full
Cash & equivalents$48.4M+80.9%
Total debt$22.7M-3.3%
Total equity$976.6M+48.8%
Total assets$1.0B+47.4%

Cash flow

See full
Operating cash flow-$12.9M-476%
CapEx$93.0K+272%
Free cash flow-$12.9M-474%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.47B-40.6%
Enterprise value$1.44B-41.6%
P/S146.9×-42.7×

Profitability

See full
Operating margin-1,442.9%-9,026pp
Net margin-1,019%-6,206pp
FCF margin-714%-2,255pp

Returns & leverage

See full
Return on equity-12.5%+0.5pp
Debt / equity0×0.0×
Current ratio35.9×-2.9×

FAQ

When did Janux Therapeutics report Q3 2025 earnings?
Janux Therapeutics (JANX) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Janux Therapeutics's Q3 2025 revenue and EPS?
Janux Therapeutics reported revenue of $10.0M and eps of $-0.39 for Q3 2025.
Did Janux Therapeutics beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.60 by $0.21.
How did Janux Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2177.9% from $439.0K a year earlier and eps grew 23.5% from $-0.51.
Where can I find Janux Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-269518) and the 10-Q periodic report (0001193125-25-269799) directly on SEC EDGAR. The filing index links above go to sec.gov.